Skip to main content
main-content

Glucagon-like peptide-1 (GLP-1) receptor agonists

medwireNews top story

AWARD 11 supports higher dulaglutide doses

Injection pen

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Remote landscape Victoria, Australia

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Chalkboard image of patient with heart failure

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

CME-accredited webcast

GLP-1RAs: Evidence From The Real World

Learn more about real world evidence of new GLP-1RAs, with Melanie Davies, Stewart Harris and Takashi Kadowaski.

Expert opinion editorial

Oral semaglutide: A technical triumph, with caveats

Balancing pros and cons

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide [read more].

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

Podcast

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?

Neil Skolnik

US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26) [Listen now]

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

medwireNews top story

PIONEER 9, 10 confirm oral semaglutide efficacy in Japanese population

Man on weight scales

Results of the PIONEER 9 and 10 trials show that oral semaglutide is efficacious in Japanese people with type 2 diabetes.

medwireNews top story

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Heart and stethoscope

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

The REWIND trial

Cardiovascular disease (illustration)
medwireNews top story

Ellipse trial: Liraglutide expands treatment options for pediatric type 2 diabetes

Injection pens

The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.

medwireNews

01-13-2021 | Dulaglutide | News

Dulaglutide reduces total CVD burden in REWIND population

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

01-11-2021 | Dulaglutide | News

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

12-21-2020 | Dulaglutide | News

Longer treatment persistence with dulaglutide vs other GLP-1 receptor agonists in type 2 diabetes

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

At a glance

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

09-14-2018 | Insulin glargine/Lixisenatide | Article

Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: Post hoc analysis of LixiLan-L

Zisman A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0507-0

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits